Get the Stockscreener App
2.05
3.76%
-0.08
After Hours:
2.02
-0.03
-1.46%
Celularity Inc stock is traded at $2.05, with a volume of 71,367.
It is down -3.76% in the last 24 hours and down -12.77% over the past month.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
See More
Previous Close:
$2.13
Open:
$2.13
24h Volume:
71,367
Relative Volume:
0.26
Market Cap:
$54.72M
Revenue:
$48.20M
Net Income/Loss:
$-35.05M
P/E Ratio:
-1.308
EPS:
-1.5673
Net Cash Flow:
$-13.02M
1W Performance:
-3.76%
1M Performance:
-12.77%
6M Performance:
+36.67%
1Y Performance:
-18.97%
1-Day Range:
$1.995
$2.165
1-Week Range:
$1.98
$2.22
52-Week Range:
$1.06
$5.22
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
2.05 | 56.85M | 48.20M | -35.05M | -13.02M | -1.5673 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
How to track smart money flows in Celularity Inc. Equity Warrant2025 EndofYear Setup & Community Consensus Trade Alerts - newser.com
Using Python tools to backtest Celularity Inc. Equity Warrant strategies2025 Earnings Impact & AI Enhanced Trading Signals - newser.com
Celularity Inc. Equity Warrant recovery potential after sell offJuly 2025 Sentiment & Community Trade Idea Sharing - newser.com
Is Celularity Inc. Equity Warrant stock cheap at current valuationJuly 2025 Recap & Safe Capital Growth Stock Tips - newser.com
Risk adjusted return profile for Celularity Inc. Equity Warrant analyzedMarket Weekly Review & Daily Risk Controlled Trade Plans - newser.com
Will Celularity Inc. Equity Warrant stock go up soonJuly 2025 Sentiment & Accurate Buy Signal Notifications - newser.com
How to monitor Celularity Inc. Equity Warrant with trend dashboards2025 Momentum Check & Community Supported Trade Ideas - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for Celularity (NASDAQ:CELU) - MarketBeat
Celularity Inc Stock Analysis and ForecastMarket Sentiment Surveys & Get Alerts Before Market Turns Ugly - earlytimes.in
Celularity Inc Equity Warrant Stock Analysis and ForecastRisk Mitigation Techniques & Low Risk Trading Plans - earlytimes.in
Can Celularity Inc. stock hit analyst price targetsJuly 2025 Update & Trade Opportunity Analysis - newser.com
Market reaction to Celularity Inc. Equity Warrant’s recent newsWeekly Gains Summary & Stepwise Trade Signal Implementation - newser.com
Will Celularity Inc. stock benefit from green energy trends2025 Valuation Update & Daily Chart Pattern Signals - newser.com
Can Celularity Inc. Equity Warrant recover in the next quarterWeekly Trade Report & Long-Term Growth Stock Strategies - newser.com
What MACD signals say about Celularity Inc.2025 Retail Activity & Free Weekly Chart Analysis and Trade Guides - newser.com
Will a bounce in Celularity Inc. Equity Warrant offer an exitEarnings Risk Summary & Advanced Technical Analysis Signals - newser.com
Celularity Stock Price, Quotes and Forecasts - Benzinga
Detecting price anomalies in Celularity Inc. Equity Warrant with AI2025 Risk Factors & AI Based Buy and Sell Signals - newser.com
Is Celularity Inc. stock cheap at current valuation2025 Growth vs Value & Daily Stock Trend Reports - newser.com
Live market analysis of Celularity Inc.Weekly Trade Recap & Free Community Consensus Stock Picks - newser.com
What drives Celularity Inc Equity Warrant stock priceIPO Market Watch & Get The Analyst Consensus With One Click - earlytimes.in
Celularity (NASDAQ:CELU) Shares Down 3.7%Here's Why - MarketBeat
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Celularity Inc Stock (CELU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hariri Robert J | Chief Executive Officer |
Apr 13 '25 |
Option Exercise |
0.00 |
3,281 |
0 |
21,482 |
| Haines John R | Senior Exec Vice President |
Apr 13 '25 |
Option Exercise |
0.00 |
1,641 |
0 |
29,698 |
| Beers David C | Chief Financial Officer |
Apr 13 '25 |
Option Exercise |
0.00 |
1,025 |
0 |
18,561 |
| Brigido Stephen | Pres., Functional Regeneration |
Feb 17 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
11,641 |
| Beers David C | Chief Financial Officer |
Feb 17 '25 |
Option Exercise |
0.00 |
12,500 |
0 |
21,932 |
| Haines John R | Senior Exec Vice President |
Feb 17 '25 |
Option Exercise |
0.00 |
20,000 |
0 |
35,092 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):